PharmaCyte Biotech Inc
For the period ended Apr 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Aug 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Market Information
Our shares of common stock are listed on the Nasdaq Capital Market (“Nasdaq”), where they have traded under ticker symbol “PMCB” since initial listing on August 10, 2021.
The following table sets forth the high and low bid quotations reported on Nasdaq through April 30, 2024 for our shares for each quarter during the two fiscal years (“FYs”) ended April 30, 2024 and 2023. The prices reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.
| Bid Price | ||
|---|---|---|
| FY 2024 | HIGH | LOW |
| First Quarter | $3.23 | $2.66 |
| Second Quarter | $2.73 | $1.94 |
| Third Quarter | $2.39 | $1.92 |
| Fourth Quarter | $2.58 | $1.94 |
| First Quarter | $2.51 | $1.95 |
| Second Quarter | $3.02 | $2.33 |
| Third Quarter | $3.10 | $2.70 |
| Fourth Quarter | $3.04 | $2.78 |
As of August 8, 2024, there were approximately 1,400 stockholders of record of our common stock. The number of stockholders of record does not include beneficial owners of our securities whose shares are held in the name of various security brokers, dealers and registered clearing agencies.
Dividend Policy
We have not paid and do not plan to pay cash dividends in the foreseeable future. In addition, the terms of the certificate of designations governing our Preferred Shares presently restricts our ability to pay dividends. Our Board will decide any future payment of dividends, depending on the results of operations, financial condition, capital requirements and other relevant factors.
Securities Authorized for Issuance under Equity Compensation Plans
See Item 12 of Part III of this Report regarding information about securities authorized for issuance under our equity compensation plans.
Recent Sales of Unregistered Securities
None.
Issuer Purchases of Equity Securities
The table below summarizes information about the Company’s purchases of its equity securities during the year ended April 30, 2024.
| Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Maximum Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under the Plans or Programs |
|---|---|---|---|---|
| May 1, 2023 – May 31, 2023 | – | – | – | $6,439,377 |
| June 1, 2023 – June 30, 2023 | – | – | – | $6,439,377 |
| July 1, 2023 – July 31, 2023 | – | – | – | $6,439,377 |
| August 1, 2023 – August 31, 2023 | – | – | – | $6,439,377 |
| September 1, 2023 – September 30, 2023 | – | – | – | $6,439,377 |
| October 1, 2023 – October 31, 2023 | 78,109 | $2.1118 | 78,109 | $6.272.775 |
| November 1, 2023 – November 30, 2023 | 60,695 | $2.1863 | 60,695 | $6.138.751 |
| December 1, 2023 – December 31, 2023 | 60,072 | $2.2901 | 60,072 | $5.999.807 |
| January 1, 2024 – January 31, 2024 | 58,066 | $2.2465 | 58,066 | $5.868.058 |
| February 1, 2024 – February 29, 2024 | 36,482 | $2.1610 | 36,482 | $5,788,433 |
| March 1, 2024 – March 31, 2024 | 353,480 | $2.4701 | 353,480 | $4,906,583 |
| April 1, 2024 – April 30, 2024 | 93,573 | $2.3797 | 93,573 | $4,681,682 |
| Total | 740,477 | $2.3502 | 740,477 | $4,681,682 |
On June 2, 2022, the Company announced that the Board had authorized a share repurchase program to acquire up to $10 million of the Company’s outstanding common stock (the “First Repurchase Program”). The number of shares of common stock repurchased on any given trading day was determined by a formula, which was based on the market price of the common stock and average daily volumes. The First Repurchase Program expired on May 30, 2024. On January 31, 2023, the Board authorized a share repurchase program to repurchase up to an additional $10 million of the Company’s outstanding common stock (the “Second Repurchase Program” and together with the First Repurchase Program, the “Repurchase Programs”). Under the Second Repurchase Program, the shares may be repurchased from time to time in open market transactions, privately negotiated block transactions or other means in accordance with applicable securities laws. For more information on the Repurchase Programs, see “Note 13 – Treasury Stock.”
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.